Gilead Sciences Inc. (GILD) Social Stream
Gilead Sciences Inc (GILD) Price Targets From Analysts
The tables below show price targets and recommendations from analysts covering Gilead Sciences Inc.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-11-14 | 17 | $100 | $63 | $78.5 | $60.67 | 29.39% |
| 2021-11-19 | 18 | $100 | $63 | $79.428 | $60.67 | 30.92% |
| 2021-12-07 | 18 | $100 | $63 | $79.266 | $60.67 | 30.65% |
| 2021-12-14 | 19 | $100 | $63 | $78.812 | $60.67 | 29.9% |
| 2021-12-22 | 19 | $100 | $63 | $79.125 | $60.67 | 30.42% |
| 2022-01-07 | 18 | $100 | $63 | $79.25 | $60.67 | 30.62% |
| 2022-01-10 | 17 | $100 | $72 | $80.714 | $60.67 | 33.04% |
| 2022-01-25 | 17 | $100 | $72 | $80.571 | $60.67 | 32.8% |
| 2022-02-01 | 18 | $100 | $72 | $80.571 | $60.67 | 32.8% |
| 2022-02-02 | 18 | $100 | $71 | $79.714 | $60.67 | 31.39% |
| 2022-02-03 | 18 | $100 | $69 | $78.928 | $60.67 | 30.09% |
| 2022-02-18 | 18 | $90 | $69 | $78.214 | $60.67 | 28.92% |
| 2022-03-07 | 18 | $90 | $65 | $77.5 | $60.67 | 27.74% |
| 2022-03-16 | 17 | $90 | $65 | $76 | $60.67 | 25.27% |
The Trend in the Analyst Price Target
GILD's average price target has moved down $1.67 over the prior 94 days.
Over the past 49 weeks, GILD's average upside potential has been 14.9%.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-05-15 | 31 | 100 | 60 | 74.540 | 68.53 | 8.77% |
| 2021-05-22 | 31 | 100 | 60 | 74.540 | 68.75 | 8.42% |
| 2021-11-14 | 17 | 100 | 63 | 78.500 | 67.48 | 16.33% |
| 2021-12-14 | 19 | 100 | 63 | 78.812 | 70.52 | 11.76% |
| 2022-02-28 | 18 | 90 | 65 | 77.500 | 60.40 | 28.31% |
GILD Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 2.24 | 6 | 1 | 10 | 0 | 0 | 17 |
The Trend in the Broker Recommendations
GILD's average broker recommendation rating improved by 0.14 over the prior 43 weeks.
Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.
- In the context of all US stocks, Gilead Sciences Inc's number of analysts covering the stock is higher than 1483.72% of them.
- In terms of how Gilead Sciences Inc fares relative to Pharmaceutical Products stocks, note that its upside potential (average analyst target price relative to current price) is higher than 251.2% of that group.
- Gilead Sciences Inc's average analyst price target is greater than 1316.23% of Pharmaceutical Products stocks.
- In the context of Pharmaceutical Products stocks, Gilead Sciences Inc's variance in analysts' estimates is lower than -397.93% of them.
In the Pharmaceutical Products industry, DNLI, DNA, and CRSP are the three stocks most similar to Gilead Sciences Inc regarding the price target and analyst recommendation information presented here.
Is GILD a Buy, Hold or Sell? See the POWR Ratings now!